Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3721 - 3728 of 12104 results
CCPA: When “Final” Doesn’t Mean What You Think It Means (with apologies to The Princess Bride)
October 14, 2020| Blog| Viewpoint
Fertility Tracking Apps Get Tough Look From States Over Privacy
October 14, 2020| News
SEC Proposes Relief from Broker-Dealer Registration for Certain Finders
October 13, 2020| Alert| Viewpoint
CMS Proposes Changes to Medicare’s Coverage Determination Criteria and Expedites Approval of Breakthrough Devices
October 13, 2020| Blog| Viewpoint
SEC’s Proposed Broker-Dealer Exemption May Apply to “Finders” for Municipal Securities
October 13, 2020| Blog| Viewpoint
Final Section 529A ABLE Plan Regulations Are Well-Intended But Will Require Further Clarification
October 12, 2020| Blog| Viewpoint
New York Passes Automatic Voter Registration: The Dawn of a New Era of Voting Rights
October 9, 2020| News
Navigating Politics in the Workplace During the Election Season
October 8, 2020| Blog| Viewpoint
News & Press Releases
Mintz Advises Oppenheimer & Co. and Initial Purchasers in $475M Convertible Senior Notes Offering by WisdomTree
August 19, 2025
Mintz represented Oppenheimer & Co., as sole book-running manager, and Craig-Hallum Capital Group and Northland Securities, as co-managers, in the private placement of $475 million aggregate principal amount of 4.625% Convertible Senior Notes due 2030 issued by WisdomTree, Inc (NYSE: WT) (“WisdomTree”). The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|